Despite evidence of systemic complement activation and activation of coagulation in cancer patient cohorts with and without COVID-19 and elevated D-dimers, C1 INH and FH levels remained within published reference ranges (Quidel MicroVue C1-Inhibitor Plus EIA. This evidence concerns the gene FH and COVID-19.